Schedule 13G ownership disclosure

Prelude Therapeutics, Inc.

Common Stock, par value $0.0001 per share · CUSIP: 74065P101

Event date: 2025-12-31

Filing-level shares
6,745,647
Percent of class
13.15%
  • Vaddi Krishna

    Shares: 6,745,647 · Class: 13.15%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0000929638-26-000626
Form type
SCHEDULE 13G/A
Filer
Prelude Therapeutics Inc
CIK
CIK 1678660
Filed
Feb 13, 2026
Reporting period
Dec 31, 2025
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub